18 employees
Ocelot Bio brings new treatment options to patients with severe liver disease.
2020
$36M
from 3 investors over 3 rounds
Ocelot Bio raised $36M on March 23, 2022
Investors: Venrock, RA Capital Management, L.P. and Vivo Capital